Cytotoxic T Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy

Affiliations

• ¹ Department of Cardiology, Cardiovascular Research Institute Maastricht (M.A.S., M.T.H.M.H., S.L.V.M.S., M.F.G.H.M.V., B.N., R.E.W.v.L., C.K., H.-P.B.-L.R., V.P.M.v.E., J.A.J.V., S.R.B.H.), Maastricht University Medical Center, the Netherlands.
• ² William Harvey Research Institute, Barts and The London School of Medicine and Dentistry (D.H., S.F., F.M.M.-B.), Queen Mary University of London, United Kingdom.
• ³ Barts Heart Centre, Barts Health NHS Trust, St Bartholomew's Hospital, London, United Kingdom (D.H., F.M.M.-B.).
• ⁴ Department of Pathology (M.T.H.M.H., X.L.), Maastricht University Medical Center, the Netherlands.
• ⁵ Netherlands Heart Institute, Utrecht, the Netherlands (M.T.H.M.H.).
• ⁶ Department of Clinical Genetics (S.L.V.M.S., J.A.J.V.), Maastricht University Medical Center, the Netherlands.
• ⁷ Maastricht UMC+ European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart) (S.L.V.M.S., J.A.J.V., S.R.B.H.).
• ⁸ Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, Herestraat 49, University of Leuven, Belgium (S.L.V.M.S., S.R.B.H.).
• ⁹ Division Clinical and Experimental Immunology, Department of Internal Medicine (P.v.P.), Maastricht University Medical Center, the Netherlands.
• ¹⁰ Centre for Inflammation and Therapeutic Innovation (F.M.M.-B.), Queen Mary University of London, United Kingdom.